The Q3 beat was driven by a one-time €70M milestone and the timing of out-licensing revenue recognition, not by core operating improvement. COVID-19 vaccine revenue continues to decline structurally. The BNT113 PFS miss and the modest DYNASTY-Breast02 results raise questions about pipeline momentum. Watch for the OS readout from AHEAD-MERIT and the upcoming GSK UPC decision on EP626 expected November 4, 2026.
Drugs in focus
BNTX drug pipeline →gotistobart
● Neutral Named in this 6-K- Impact
- Phase
- Phase 3
- Time to market
- At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
- Next catalyst
- None dated
What to watchThe key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.
- ◆ BNT323 4/10 Phase 3 Named in filing
- ▼ tenumomeran 4/10 Phase 2/3 (pivotal) Named in filing
- ● Comirnaty 3/10 Approved Named in filing
- ● beruzatatug pelitecan 2/10 Preclinical / Discovery (no clinical trials registered) Named in filing
- ● sacituzumab drozuntecan 2/10 Phase 1/2 Named in filing
- 2 more · All BNTX drugs, catalysts & trials →
Price Chart
Executive Summary
BioNTech reported Q3 2026 revenue of €1,289.2M, down 15% YoY from €1,518.9M, driven by a 35% decline in COVID-19 vaccine revenue to €554.3M. The company posted a net profit of €184.5M (€0.73 diluted EPS), versus a net loss of €28.7M in Q3 2025, aided by €683.0M in out-licensing revenue (including a €70M milestone) and lower prior-year patent litigation settlements. R&D spending rose 32% to €748.1M, and the company recorded €223.2M in impairment and restructuring charges. The AHEAD-MERIT Phase 2/3 trial for BNT113 missed its PFS endpoint, while the DYNASTY-Breast02 Phase 3 trial met its primary endpoint with modest PFS benefit but showed limited potential in the current treatment landscape.
Key Financial Metrics
Key Facts
- Q3 2026 revenue €1,289.2M, down 15% YoY (€1,518.9M); COVID-19 vaccine revenue fell 35% to €554.3M
- Q3 2026 net profit €184.5M (€0.73 diluted EPS) vs net loss €28.7M in Q3 2025
- Out-licensing revenue of €683.0M included a €70.0M development milestone from an out-licensed R&D program
- R&D expenses rose 32% to €748.1M, driven by IO/ADC programs and CureVac integration
- Impairment losses on intangible assets totaled €191.7M in Q3 2026, including €96.0M on a technology asset due to a shift to next-gen AI models
- Pipeline prioritization costs were €93.1M in Q3 2026, including €42.2M impairment and €19.7M employee-related restructuring
- Cash, cash equivalents and security investments totaled €16,163.8M as of September 30, 2026
- AHEAD-MERIT Phase 2/3 trial for BNT113 missed its PFS endpoint; OS evaluation continues
- DYNASTY-Breast02 Phase 3 trial met its primary endpoint with modest PFS improvement; OS data not mature
- EP949 patent finally revoked by EPO, reducing Moderna litigation risk in multiple jurisdictions
Financial Impact
Q3 2026 revenue €1,289.2M (down 15% YoY); net profit €184.5M vs loss €28.7M; adjusted net profit €440.9M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| COVID-19 vaccine | $554.3M | -35.0% |
| Out-licensing | $683.0M | +11.4% |
| Other revenues | $51.9M | -1.3% |
Risk Factors
- Ongoing COVID-19 vaccine revenue decline as pandemic demand wanes
- BNT113 AHEAD-MERIT trial missed PFS endpoint; OS outcome uncertain
- DYNASTY-Breast02 showed modest PFS benefit with limited commercial potential per management
- Multiple pending patent litigations (Moderna EP437, Arbutus/Genevant, GSK EP626, Bayer, Translate Bio) create contingent liability risk
- Rising R&D spend (+32% YoY) and restructuring costs pressure margins
- European Commission audit of CureVac's €450M advance payment could result in repayment obligation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000081 |
| Document: form6-kq32026quarterlyrepo.htm | 0001776985-26-000081 |
| Document: 0001776985-26-000081-index-headers.html | 0001776985-26-000081 |
| Document: 0001776985-26-000081-index.html | 0001776985-26-000081 |
| Document: 0001776985-26-000081.txt | 0001776985-26-000081 |
| Earnings Context (Synthetic; results releases only) | 0001776985-26-000081 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 Viewing No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers